BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 11867687)

  • 1. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.
    de la Fuente MT; Casanova B; Moyano JV; Garcia-Gila M; Sanz L; Garcia-Marco J; Silva A; Garcia-Pardo A
    J Leukoc Biol; 2002 Mar; 71(3):495-502. PubMed ID: 11867687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax.
    de la Fuente MT; Casanova B; Garcia-Gila M; Silva A; Garcia-Pardo A
    Leukemia; 1999 Feb; 13(2):266-74. PubMed ID: 10025901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
    de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
    Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of p53 in alpha4beta1 integrin-mediated resistance of B-CLL cells to fludarabine.
    de la Fuente MT; Casanova B; Cantero E; Hernández del Cerro M; Garcia-Marco J; Silva A; Garcia-Pardo A
    Biochem Biophys Res Commun; 2003 Nov; 311(3):708-12. PubMed ID: 14623330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia.
    Silva KL; Vasconcellos DV; Castro ED; Coelho AM; Linden R; Maia RC
    Apoptosis; 2006 Feb; 11(2):277-85. PubMed ID: 16502265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
    Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
    Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
    Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
    McElligott AM; Maginn EN; Greene LM; McGuckin S; Hayat A; Browne PV; Butini S; Campiani G; Catherwood MA; Vandenberghe E; Williams DC; Zisterer DM; Lawler M
    Cancer Res; 2009 Nov; 69(21):8366-75. PubMed ID: 19826055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
    Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
    Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism.
    Mengubas K; Riordan FA; Bravery CA; Lewin J; Owens DL; Mehta AB; Hoffbrand AV; Wickremasinghe RG
    Oncogene; 1999 Apr; 18(15):2499-506. PubMed ID: 10229201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
    Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
    Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P; Corallini F; Barbarotto E; Melloni E; di Iasio MG; Tiribelli M; Zauli G
    J Cell Physiol; 2006 Apr; 207(1):158-64. PubMed ID: 16270354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand.
    Buske C; Gogowski G; Schreiber K; Rave-Fränk M; Hiddemann W; Wörmann B
    Exp Hematol; 1997 Apr; 25(4):329-37. PubMed ID: 9131008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.
    Vilpo J; Koski T; Vilpo L
    Haematologica; 2000 Aug; 85(8):806-13. PubMed ID: 10942926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
    Amigo-Jiménez I; Bailón E; Ugarte-Berzal E; Aguilera-Montilla N; García-Marco JA; García-Pardo A
    PLoS One; 2014; 9(6):e99993. PubMed ID: 24956101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
    Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular biology examination in chronic lymphocytic leukemia].
    Telek B; Rejtó L; Mezei G; Karászi E; Kappelmayer J; Balázs M; Kiss A; Ujj G; Rák K; Udvardy M
    Orv Hetil; 2001 Apr; 142(16):833-7. PubMed ID: 11340945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
    McConkey DJ; Chandra J; Wright S; Plunkett W; McDonnell TJ; Reed JC; Keating M
    J Immunol; 1996 Apr; 156(7):2624-30. PubMed ID: 8786328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
    Klobusická M; Kusenda J; Babusíková O
    Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.